EndpointsJul 171 min read

GSK halts Phase 3 chronic cough drug camlipixant, jeopardizing $2 billion Bellus Health acquisition

Jul 17, 2026read at Endpoints ↗Negative

GSK announced it is ending development of camlipixant, a drug aimed at treating refractory chronic cough, after completing Phase 3 trials.

The move comes as the company proceeds with its planned $2 billion acquisition of Bellus Health, the developer of camlipixant, raising questions about the strategic fit of the asset.

Analysts say the setback could impact Bellus Health’s valuation and may prompt GSK to reassess its respiratory pipeline.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyout”

read at Endpoints ↗

82 words · retrieved Jul 17

sharex / twitter linkedin

GSK halts Phase 3 chronic cough drug camlipixant, jeopardizing $2 billion Bellus Health acquisition

comments(0)

GSK halts Phase 3 chronic cough drug camlipixant, jeopardizing $2 billion Bellus Health acquisition

comments(0)

GSK halts Phase 3 chronic cough drug camlipixant, jeopardizing $2 billion Bellus Health acquisition

comments(0)

GSK halts Phase 3 chronic cough drug camlipixant, jeopardizing $2 billion Bellus Health acquisition

comments(0)

GSK halts Phase 3 chronic cough drug camlipixant, jeopardizing $2 billion Bellus Health acquisition

GSK halts Phase 3 chronic cough drug camlipixant, jeopardizing $2 billion Bellus Health acquisition